919783-22-5

919783-22-5 structure

919783-22-5 structure

Name: AZD-1656
Chemical Name: AZD1656
CAS Number: 919783-22-5
Molecular Formula: C₂₄H₂₆N₆O₅
Molecular Weight: 478.500
Catalog: Signaling Pathways Metabolic Enzyme/Protease Glucokinase
Create Date: 2018-06-03 08:02:47
Modify Date: 2024-01-01 19:58:38
AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research[1][2][3].

Name	AZD1656
Synonyms	660M185X4D 3-{[5-(1-Azetidinylcarbonyl)-2-pyrazinyl]oxy}-5-{[(2S)-1-methoxy-2-propanyl]oxy}-N-(5-methyl-2-pyrazinyl)benzamide AZD1656 Benzamide, 3-[[5-(1-azetidinylcarbonyl)-2-pyrazinyl]oxy]-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methyl-2-pyrazinyl)-

Description	AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research[1][2][3].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Glucokinase Research Areas >> Metabolic Disease
Target	EC50: 60 nM (Glucokinase)[2]
In Vivo	AZD1656 (0-9 mg/kg; oral gavage; daily; for 8 weeks; C57BL/6 mice) treatment shows lowered blood glucose and glucose excursion and raised insulin. Liver mRNA levels for various ChREBP target genes including carbohydrate response element binding protein beta isoform (ChREBP-β), G6pc, Pklr, Acly, Acac and Gpd2 are increased by AZD1656[1]. Animal Model: C57BL/6 mice[1] Dosage: 0 mg/kg, 2 mg/kg, 4.5 mg/kg, 9 mg/kg Administration: Oral gavage; daily; for 8 weeks Result: Administered 2 hours before the oral glucose tolerance test, lowered blood glucose and glucose excursion and raised insulin.
References	[1]. Brian E Ford, et al. Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge. Diabetes Obes Metab. 2020 Jun 10. [2]. Medicinal Chemistry, et al. Design and Development of the Glucokinase Activator AZD1656. Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 1, 185-220. [3]. Terri Mitchard, et al. The novel use of a heterozygous knockout mouse for embryofetal development assessment of a glucokinase activator. Birth Defects Res B Dev Reprod Toxicol. 2014 Apr;101(2):152-61.

Density	1.3±0.1 g/cm3
Boiling Point	635.0±55.0 °C at 760 mmHg
Molecular Formula	C₂₄H₂₆N₆O₅
Molecular Weight	478.500
Flash Point	337.8±31.5 °C
Exact Mass	478.196472
LogP	-0.21
Vapour Pressure	0.0±1.9 mmHg at 25°C
Index of Refraction	1.631
Storage condition	-20℃